$AKBA Akebia Therapeutics, attracting Dip Buyers

Long

Akebia Therapeutics, Inc. (NASDAQ:AKBA)

NASDAQ:AKBA Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our App on Google Play! dexwirenews.com/APP

2) Text Message Notifications: dexwirenews.com/SMS

3) Telegram: t.me/DEXWireNews

4) Follow Us on our Social Networks

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.